

April 15, 2001

Dear Sir,

This proposal only brings gene therapy and Xenotransplantation in compliance with the same types of information already released to the public by other government agencies.

Because of grave public health risks, disclosure should include additional information such as physicians medical centers and so on - make public all information except trade secrets and patient identification. The FDA must assume the sole responsibility for summarizing and distributing information submitted by the research sponsor, rather than leave it to the sponsor's discretion.

Because of the public health risks, ethical issues, cost uncertainty and the inability to adequately assess other alternatives, all xenotransplantation clinical trials should stop.

Pocket number OON-0989.

Thank you-

George & Myra Hurst  
78 Pine Avenue  
Riverside-Illinois  
60546

OON-0989

C135



Mr. George Hurst  
78 Pine Ave.  
Riverside, IL 60546



U.S. Food and Drug Administration  
Dockets Management Branch  
5630 Fishers Lane  
Room 1061  
HFA-305  
Rockville, MD-  
20852

20257/0001 bbbbbbdbdbdbdbdbdbdbdbdbdbdbdbdbdb